Combination of Lithium and Duloxetine in 2 Depressed Patients Refractory to Duloxetine Monotherapy

References

• 1 Dugan SE, Fuller MA. Duloxetine: a dual reuptake inhibitor.  Ann Pharmacother. 2004;  38 2078-2085
• 2 Girardi P, Pompili M, Innamorati M. et al . Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods.  Hum Psychopharmacol. 2009;  24 177-190
• 3 Adli M, Bauer M, Rush AJ. Algorithms and collaborative-care systems for depression: are they effective and why?.  A systematic review. Biol Psychiatry. 2006;  59 1029-1038
• 4 Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials.  J Clin Psychiatry. 2007;  68 935-940
• 5 Bschor T, Lewitzka U, Sasse J. et al . Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms.  Pharmacopsychiatry. 2003;  36 (S 03) 230-234
• 6 Fleurence R, Williamson R, Jing Y. et al . A systematic review of augmentation strategies for patients with major depressive disorder.  Psychopharmacol Bull. 2009;  42 57-90
• 7 Baumann P, Nil R, Souche A. et al . A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation.  J Clin Psychopharmacol. 1996;  16 307-314
• 8 Katona CL, Abou-Saleh MT, Harrison DA. et al . Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine.  Br J Psychiatry. 1995;  166 80-86
• 9 Ontiveros A, Fontaine R, Elie R. Refractory depression: the addition of lithium to fluoxetine or desipramine.  Acta Psychiatr Scand. 1991;  83 188-192
• 10 Bertschy G, Ragama-Pardos E, Ait-Ameur A. et al . Lithium augmentation in venlafaxine non-responders: an open study.  Eur Psychiatry. 2003;  18 314-317
• 11 Yates WR, Wesner RB, Thompson R. Organic mood disorder: a valid psychiatry consultation diagnosis?.  J Affect Disord. 1991;  22 37-42
• 12 Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder.  CNS Drugs. 2007;  21 581-609
• 13 Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder.  J Clin Psychiatry. 2009;  70 (S 06) 16-25
• 14 Hoencamp E, Haffmans J, Dijken WA. et al . Lithium augmentation of venlafaxine: an open-label trial.  J Clin Psychopharmacol. 2000;  20 538-543
• 15 Adan-Manes J, Novalbos J, Lopez-Rodriguez R. et al . Lithium and venlafaxine interaction: a case of serotonin syndrome.  J Clin Pharm Ther. 2006;  31 397-400
• 16 Mekler G, Woggon B. A case of serotonin syndrome caused by venlafaxine and lithium.  Pharmacopsychiatry. 1997;  30 272-273
• 17 Waring WS. Management of lithium toxicity.  Toxicol Rev. 2006;  25 221-230

Correspondence